EDSA Stock Overview
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.
Edesa Biotech, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.03|
|52 Week High||US$12.00|
|52 Week Low||US$1.30|
|1 Month Change||22.29%|
|3 Month Change||11.54%|
|1 Year Change||-51.78%|
|3 Year Change||-49.75%|
|5 Year Change||n/a|
|Change since IPO||-60.96%|
Recent News & Updates
Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Edesa Biotech press release (NASDAQ:EDSA): Q3 GAAP EPS of -$0.37 beats by $0.06. At June 30, 2022, Edesa had cash and cash equivalents of $12.81 million and working capital of $9.52 million.
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|EDSA||US Biotechs||US Market|
Return vs Industry: EDSA underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: EDSA underperformed the US Market which returned -9% over the past year.
|EDSA Average Weekly Movement||10.8%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: EDSA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EDSA's weekly volatility has decreased from 19% to 11% over the past year.
About the Company
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10.
Edesa Biotech, Inc. Fundamentals Summary
|EDSA fundamental statistics|
Is EDSA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EDSA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.19|
|Net Profit Margin||0.00%|
How did EDSA perform over the long term?See historical performance and comparison